Publications by authors named "Jashin J Wu"

309 Publications

Epidemiology and Characterization of Atopic Dermatitis in East Asian Populations: A Systematic Review.

Dermatol Ther (Heidelb) 2021 Apr 9. Epub 2021 Apr 9.

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Introduction: As atopic dermatitis (AD) grows increasingly prevalent in Asian populations worldwide, understanding how environmental, genetic, and cultural factors uniquely influence AD in Asians is essential for informing disease management. Our objectives were to characterize the epidemiology of AD in East Asian populations with sensitivity to the changing demographics of AD in these populations and the effects of urbanization and immigration.

Methods: A systematic review was performed on epidemiologic studies of AD in East Asian populations over the past 10 years.

Results: There is a rising prevalence of both pediatric and adult AD in Asian populations worldwide, particularly in Asians living in urban areas. Studies suggest that the children of Asian immigrants may be at higher risk for developing AD, potentially resulting from epigenetic phenomena unique to immigrant populations. A number of genetic polymorphisms implicated in AD are shared by Asian populations around the world and appear to be rare among other ethnic populations.

Conclusions: As the prevalence of AD continues to increase in Asian populations, it is important to understand its distinct genetic and pathophysiologic profile in these populations, as well as characterize the cultural beliefs and practices surrounding its treatment. Future research should aim to capitalize on our growing understanding of pathophysiologic differences to inform the most promising treatments for AD in Asians. Additionally, the impact of immigration on AD suggests that further investigation of these trends may lead to a greater understanding of the epigenetics of AD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-021-00516-wDOI Listing
April 2021

Characterization of Non-Responders to IL-17 inhibitors in Moderate to Severe Psoriasis Patients Enrolled in the Corrona® Psoriasis Registry.

J Eur Acad Dermatol Venereol 2021 Apr 8. Epub 2021 Apr 8.

Corrona LLC, Waltham, MA, USA.

While interleukin-17 (IL-17) inhibitors are effective for many patients with psoriasis, there is limited real-world data characterizing patients who respond or do not respond to this biologic class. Identification of patient characteristics associated with response to this class of medication would present a significant advantage for both patients and physicians. For this reason, we have conducted a retrospective characterization of non-response to IL-17 inhibitors in patients with moderate-severe psoriasis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.17270DOI Listing
April 2021

Free open access data sources for dermatology researchers.

Dermatol Online J 2021 Feb 15;27(2). Epub 2021 Feb 15.

Dermatology Research and Education Foundation, Irvine, CA.

Free open access data sources are a valuable tool for dermatology researchers and may uncover crucial information about dermatological diseases and delivery of dermatological care. This short review discusses six open access data sources including: National Health and Nutrition Examination Survey (NHANES), National Health Interview Survey (NHIS), National Survey of Children's Health (NSCH), National Ambulatory Medical Care Survey (NAMCS)/National Hospital Ambulatory Medical Care Survey (NHAMCS), Centers for Medicare and Medicaid Services (CMS), and Gene Expression Omnibus (GEO). We explain the role of each data source in dermatology and provide examples of past studies, which have used these data repositories.
View Article and Find Full Text PDF

Download full-text PDF

Source
February 2021

An evaluation of shade-seeking and long-sleeved shirt use in Asian Americans.

J Am Acad Dermatol 2021 Mar 23. Epub 2021 Mar 23.

Dermatology Research and Education Foundation, Irvine, CA, USA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2021.03.057DOI Listing
March 2021

Preliminary outcomes of 2020-2021 dermatology residency application cycle and adverse effects of COVID-19.

J Am Acad Dermatol 2021 Mar 17. Epub 2021 Mar 17.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2021.03.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965841PMC
March 2021

Association between psoriasis and thyroid dysfunction among US adults in the 2009-2014 National Health and Nutrition Examination Survey.

J Am Acad Dermatol 2021 Mar 17. Epub 2021 Mar 17.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2021.03.030DOI Listing
March 2021

Asian Americans are less likely to wear sunscreen compared with non-Hispanic whites.

J Am Acad Dermatol 2021 Feb 26. Epub 2021 Feb 26.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.12.079DOI Listing
February 2021

The influence of race/ethnicity and skin reaction to sun on sunscreen use.

J Am Acad Dermatol 2021 Feb 4. Epub 2021 Feb 4.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2021.01.101DOI Listing
February 2021

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral.

Dermatol Ther (Heidelb) 2021 Apr 6;11(2):499-512. Epub 2021 Feb 6.

Eli Lilly and Company, Indianapolis, IN, USA.

Introduction: A number of treatments for atopic dermatitis (AD) are available; however, long-term treatment patterns and healthcare consumption in patients with AD are poorly described.

Methods: We conducted a registry-based longitudinal drug utilization study among Danish patients with AD that were referred to their first-ever visit at hospital-based dermatology clinics. Their first visit was in the period between 1 January 2005 and 31 December 2012, and patients were followed up to 5 years after their first visit.

Results: In total, 8213 people with a first-time hospital dermatologist contact for AD were included in the study (3514 aged 0-9 years, 1501 aged 10-19 years, 3198 aged 20 years or older). At first visit, a baseline history of moderately potent topical corticosteroid (TCS) use was seen among 46.6% of children (0-9 years), whereas potent or very potent TCS use was more frequently among older individuals (e.g., 51.1% and 25.6% of people aged 50 years or older had used potent and very potent TCS, respectively). The median (interquartile range) annual number of visits to general practitioners was 4 (2-7) for children and 5 (2-8) for adults, in the 12 months prior to referral. Three years after referral, these numbers had decreased to 2 (1-4) and 3 (1-6), respectively. In the first year after referral, 6% of patients were prescribed systemic corticosteroids, whereas other systemic therapies were used in 5% or less.

Conclusions: After referral, low proportions of patients received systemic treatment, or potent TCS. These findings highlight considerable differences in treatment patterns between general practitioners and private practice dermatologists, compared with hospital-based dermatologists, and emphasize the need for better adherence to evidence-based treatment guidelines.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-021-00491-2DOI Listing
April 2021

Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys.

J Am Acad Dermatol 2021 Mar 23;84(3):767-769. Epub 2020 Oct 23.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.10.035DOI Listing
March 2021

Dermatologists as social media contributors during the COVID-19 pandemic.

Cutis 2020 11;106(5):245-246

Research and Education Foundation, Irvine, California, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0112DOI Listing
November 2020

Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis in Pediatric Patients.

Cutis 2020 Nov;106(5):257-260;E3

Dermatology Research and Education Foundation, Irvine, California, USA.

In November 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released their recommendations regarding management of psoriasis in pediatric patients. The guidelines include information on quantification of disease severity, identification of triggers, assessment of comorbidities, and therapeutics specific to children with psoriasis. This review aims to highlight the most clinically significant considerations for dermatologists when managing pediatric psoriasis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0115DOI Listing
November 2020

Abrocitinib for atopic dermatitis.

Lancet 2021 01;397(10270):195-196

Dermatology Research and Education Foundation, Irvine, CA 92620, USA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(21)00036-2DOI Listing
January 2021

Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.

J Dermatolog Treat 2021 Jan 12:1-3. Epub 2021 Jan 12.

Dermatology Research and Education Foundation, Irvine, CA, USA.

The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgaris. Without specific data studying rituximab use and susceptibility of SARS-CoV-2, we hope to utilize available data in order to assist clinician decision making for rituximab in the context of the pandemic.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1870648DOI Listing
January 2021

Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry.

J Comp Eff Res 2021 Feb 23;10(2):157-167. Epub 2020 Dec 23.

Eli Lilly & Company, Indianapolis, IN 46225, USA.

Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other biologics for psoriasis treatment in North American dermatological practices. Characteristics of patients ascertained at registry enrollment are described via means and frequencies. Compared with other biologic initiators, ixekizumab initiators had: longer disease duration (17.1 vs 15.1 years); more were considered least severe by body surface area (33 vs 26%); moderate-to-severe by IGA (56 vs 48%); were biologic-experienced (80 vs 52%); obese (54 vs 47%); and experienced greater impact in work productivity (5.3 vs 2.9%) versus other biologic initiators. Psoriasis patients initiating ixekizumab had more severe disease, biologic experience, and worse patient-reported outcomes than those initiating other biologics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2020-0113DOI Listing
February 2021

A response to "Male balding is a major risk factor for severe COVID-19".

J Am Acad Dermatol 2021 02 24;84(2):e87-e88. Epub 2020 Oct 24.

Dermatology Research and Education Foundation, Irvine, CA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.10.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585501PMC
February 2021

A response to "Male balding is a major risk factor for severe COVID-19".

J Am Acad Dermatol 2021 02 24;84(2):e87-e88. Epub 2020 Oct 24.

Dermatology Research and Education Foundation, Irvine, CA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.10.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585501PMC
February 2021

Ruxolitinib cream for the treatment of vitiligo.

Lancet 2020 11;396(10264):1735-1736

Dermatology Research and Education Foundation, Irvine, CA 92620, USA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)32469-7DOI Listing
November 2020

Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis.

Cutis 2020 Oct;106(4):199-205

Dermatology Research and Education Foundation, Irvine, California, USA.

Psoriasis is an inflammatory disease with both skin and joint manifestations. Focused biologics have been developed to target specific cytokines implicated in psoriasis and are becoming increasingly utilized. Recently, the advent of newer biologics, including IL-17, IL-12/IL-23, and IL-23 inhibitors, have garnered interest as promising treatments for psoriasis and other inflammatory conditions. Although IL-17 and IL-23 have been studied in the pathophysiology of psoriasis, they also play a central role in immunologic defenses, including those against fungi. Therefore, use of these interleukin inhibitors may theoretically impair the immune system against deep fungal infections. We reviewed the available literature investigating the risk for invasive fungal infections in patients treated with IL-17 and IL-23 inhibitors for psoriasis or other inflammatory conditions. Randomized controlled trials (RCTs), including extended trials and clinical trials, were reviewed, and we found that although there was a small number of patients who developed superficial candidiasis, there were no reports of invasive fungal disease. Although these results support the safety and the low risk for deep fungal infection with these biologics, caution is still warranted, as these medications are relatively new. Appropriate screening and management of fungal disease should still be practiced when utilizing these medications in the treatment of psoriasis and other inflammatory conditions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0088DOI Listing
October 2020

Use of Topical Tazarotene for the Treatment of Acne Vulgaris in Pregnancy: A Literature Review.

J Clin Aesthet Dermatol 2020 Sep 1;13(9):E59-E65. Epub 2020 Sep 1.

Dr. Han is with the Icahn School of Medicine at Mount Sinai in New York, New York.

A concern with the increasing use of prescription drugs during pregnancy is teratogenic risk. This risk is undetermined for most drugs approved in the United States (US) from 2000 to 2010. Acne and psoriasis are chronic diseases that typically occur during the child-bearing years, and as topical retinoids are recommended for both acne and psoriasis treatment, is it possible for women to be exposed to a topical retinoid during pregnancy. Pharmacokinetic studies show relatively low systemic exposure from topical retinoids, but the exposure levels that could lead to teratogenicity in humans are unknown. Tazarotene, a topical retinoid, was US Food and Drug Administration (FDA) approved for both acne and psoriasis using pharmacokinetic data from psoriasis studies, which estimated the data based on use of tazarotene on up to 20% body surface area. As such, under both the previous and current FDA pregnancy labeling, tazarotene is not recommended for use during pregnancy. The goal of this literature review was to provide historical context for the pregnancy labeling rule for tazarotene compared with other approved retinoids and gather available data on tazarotene- and retinoid-related pregnancy outcomes. While there are case reports of topical tretinoin and adapalene exposure , it is unclear if either affected fetal development. In terms of topical tazarotene, there are currently limited data regarding pregnancy outcomes after exposure. Additional case reports and outcomes studies are needed to further explore the safety of topical tazarotene in pregnancy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577328PMC
September 2020

Management of psoriasis with biologics in clinical practice: an update for 2020.

Cutis 2020 Aug;106(2S):21-24

Dermatology Research and Education Foundation, Irvine, California, USA.

This article aims to address updates on recent clinical trial findings (April 2019 to April 2020) regarding biologic therapy initiation and maintenance for adult patients. Prescribers should use this update as guidance for determining the appropriate biologic class based on patient characteristics and for approaching biologic-experienced patients with refractory psoriasis. This update also may serve as a reference for the recommended dosing regimens of the 11 approved biologics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0035DOI Listing
August 2020

Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.

J Drugs Dermatol 2020 10;19(10):956-959

Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), and good skin care practices. As chronic TCS or TCI can lead to the development of adverse effects, there is a need for safe, alternative treatments for patients with resistant AD. A systemic literature review was performed to examine the safety and efficacy of topical agents currently in phase II and phase III clinical trials for AD. Our team searched the databases, PubMed, Google Scholar, and ClinicalTrials.gov, on March 2020 for studies pertaining to the use of topical agents in AD. Key words included each drug (tapinarof, crisaborole, ARQ-151 cream, ruxolitinib) or "topical agents"; combined with "atopic dermatitis"; Articles published within the last 5 years were included as references. References within retrieved articles were also reviewed to identify potentially missed studies. A total of 24 articles were included in this review. Tapinarof, crisaborole, and ruxolitinib lead to statistically significant improvements in multiple disease severity scores. ARQ-151 cream achieved statistical significance in secondary endpoints, including vIGA-AD and EASI-75, but not in the primary endpoint of the study. All topical agents were well-tolerated by study participants. The findings demonstrate that tapinarof, crisaborole, ARQ-151 cream, and ruxolitinib are safe, effective treatment options for patients with mild to moderate AD. J Drugs Dermatol. 2020;19(10):956-959. doi: 10.36849/JDD.2020.5214.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.36849/JDD.2020.5214DOI Listing
October 2020

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials.

J Dermatolog Treat 2020 Oct 21:1-9. Epub 2020 Oct 21.

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: The influence of comorbidities on the efficacy and safety of biologic therapies in psoriasis has not been rigorously explored.

Objective: To assess the incremental burden of comorbidities on clinical efficacy and safety of secukinumab vs. etanercept and placebo among patients with plaque psoriasis pooled from 4 phase 3 trials.

Methods: Efficacy was assessed at week 12 according to achievement of Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA; modified 2011) responses. Efficacy comparisons between treatment arms stratified by comorbidity status were made using logistic regression analysis with nonresponder imputation. Relationships between baseline characteristics and clinical responses were evaluated by tests.

Results: Of 2401 patients, 1469 (61.2%) had ≥1 active baseline comorbidity. Regardless of comorbidity status, patients receiving secukinumab were more likely to achieve PASI and IGA responses than those receiving etanercept or placebo at week 12 ( < .05 for all comparisons). Body weight of ≥90 kg was consistently associated with a decreased likelihood of achieving PASI and IGA responses ( < .01 for all comparisons). Safety was comparable across treatment arms stratified by comorbidity.

Conclusions: Secukinumab improved clinical outcomes and was well tolerated in patients with concomitant baseline comorbid conditions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1832187DOI Listing
October 2020

Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic".

J Am Acad Dermatol 2021 01 30;84(1):e31-e32. Epub 2020 Sep 30.

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.09.069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526625PMC
January 2021

Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Phototherapy.

Cutis 2020 Aug;106(2):82-86

Dermatology Research and Education Foundation, Irvine, California, USA.

In July 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released an updated set of guidelines regarding the use of phototherapy to manage adult patients with psoriasis. Treatment with light of various wavelengths is reviewed, with a focus on modalities utilizing UV light. These guidelines provide the most up-to-date evidence regarding dosing, indications, contraindications, and adverse effects of phototherapy alone and in combination with other treatments for psoriasis. This review aims to present the recommendations in a form that is readily translatable to clinical practice.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0026DOI Listing
August 2020

Topical Scar Treatment Products for Wounds: A Systematic Review.

Dermatol Surg 2020 12;46(12):1564-1571

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

Background: There is an increasing number of over-the-counter topical products that are said to prevent pathologic scar formation and improve scar cosmesis. However, robust clinical data are lacking to substantiate these claims and to guide selection of topical products.

Objective: To determine the effectiveness of topical scar management products, including silicone gel, Allium cepa onion extract, vitamin E, trolamine, and microporous tape.

Methods And Materials: A PubMed search (2005-2019) was performed to identify studies of topical scar management products. Randomized controlled trials (RCTs), quasi-RCTs, meta-analyses, and controlled clinical trials were included for analysis.

Results: A total of 34 trials were included in this study. Of the 16 trials investigating silicone gel sheets, numerous high-quality RCTs found that silicone gel sheets and silicone gels significantly improved scar outcomes. Only a limited number of studies supported the effectiveness of onion extract, vitamin E, trolamine, and microporous tape products.

Conclusion: Silicone gel products are an effective noninvasive treatment to prevent formation of pathologic scars and improve mature scars. Further high-quality studies are needed to elucidate the long-term effectiveness of these therapies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000002712DOI Listing
December 2020

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.

Adv Ther 2020 11 10;37(11):4491-4518. Epub 2020 Sep 10.

Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.

With the increasing availability of biosimilars, the practice of switching therapies for non-medical reasons between an originator biologic and an analogous biosimilar has become more common. The evidence to support this practice mostly comes from single-switch randomized controlled trials (RCTs) and real-world (RW) evidence studies. However, as more biosimilars of the same originator enter the market, multiple switching events between originators and biosimilars is becoming a reality, despite limited evidence to support the efficacy and safety of such practice. Some countries have established guidelines, policies, or laws related to interchangeability and/or automatic substitution, whereas others have left these practices unregulated or controlled by other components of the healthcare system. Collectively, guidelines on single non-medical switching are often vague, with even less focus given to multiple non-medical switching, leaving this practice mostly unregulated. This narrative review will first discuss the current regulatory perspectives on non-medical switching and challenges associated with switching therapies, particularly with the availability of multiple biosimilars. We will then review the current evidence from RCTs and RW studies in the light of three different multiple-switch scenarios currently taking place in clinical practice: switching between an originator and a single biosimilar, switching between biosimilars of the same originator, and the clinical practice of switching back to the originator (i.e., switchbacks) after a failure of the initial non-medical switch to the analogous biosimilar.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01472-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547992PMC
November 2020